Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG141 (Nairecovir) + NAs in Chronic Hepatitis B Extension Study
NCT07588009Phase 3Not yet recruiting
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jan 2028
01
Overview
Phase 3, open-label, single-arm trial in Chronic Hepatitis B (CHB), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Safety of GST-HG141 combined with NAs treatment at 52 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07588009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588009.